Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
T101 is speaking to us through pre-market trades imho.... It means something... I hope it's something good too!
Don't pay attention to pphm's chart.... They don't work.... Never did.
Rule 201 of Regulation SHO – will be based on a “circuit breaker” that, when triggered, would prevent short sales from being effected at a price at or below the National Best Bid (NBB) for the remainder of the day and the following day.
I bet we get news tomorrow.. Imho
Yes cheynew I knew this.... I was replying to an earlier post of his... Thanks.
You sure about this Lemmy? Thoughts please.
Mission control to Loof... Mission control to Loof... Do you read me?
I was day dreaming the same thing today!...
Agree!!.... It's not gonna happen... Every time the pps was under a buck (many times)... We never got delisted... It was always talked about, but never happened...
101 pps... 101 volume's... Whats up with this 101?
What the heck is it with the 101 trades the last few days?
Expecting Big Things From Peregrine Pharmaceuticals Inc (NASDAQ:PPHM)
JANUARY 25, 2016 BY ALEX CARLSON 1 COMMENT
A lot has already happened with Peregrine Pharmaceuticals Inc (NASDAQ:PPHM) since our January 4th article titled “Don’t Bet Against Peregrine Pharmaceuticals In 2016.” First, the company announced a new research collaboration with the National Comprehensive Cancer Network to expand the company’s ongoing clinical research and development of bavituximab for the treatment of a range of tumors. This affiliation is a pretty big deal for PPHM. NCCN, a not-for-profit alliance of 26 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Peregrine will fund multiple investigator-initiated clinical and correlative studies with bavituximab in multiple cancers at NCCN Member Institutions and their affiliate community hospitals through a $2 million research grant to NCCN’s Oncology Research Program (ORP). NCCN will be responsible for oversight and monitoring of the clinical studies through the research grant.
Peregrine expects results from this collaboration to further support the ongoing development of bavituximab as a key component of various combination cancer treatments. Bavituximab is currently being evaluated in combination with docetaxel (chemotherapy) for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in the ongoing Phase III SUNRISE trial. In addition, as part of its recently formed collaboration with AstraZeneca, Peregrine expects to initiate a global Phase II study of bavituximab in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in patients with previously treated squamous or non-squamous NSCLC. The company will also be evaluating bavituximab with chemotherapy combinations in HER2-negative breast cancer.
Second, PPHM is expanding its bavituximab clinical program in lung, breast and other cancers. The planned trials include a Phase II NSCLC trial in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), and a Phase II trial in early stage triple negative breast cancer (TNBC). These are in addition to the recently initiated Phase II/III study in combination with chemotherapy in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). The company expects that initial data from these trials may be available in late 2016 or early 2017. Additionally, the company looks forward to the initiation of additional trials of bavituximab combinations through its ongoing collaborations with AstraZeneca and NCCN. CEO Stephen King pretty much summed it up:
“As we wrap up enrollment in the SUNRISE trial, we recognize that we are at an ideal juncture to continue expanding the potential of bavituximab with standard of care and immunotherapy combinations in multiple solid tumor types. Combined with the SUNRISE trial, the new studies we have planned can help solidify the potential of bavituximab in NSCLC while significantly expanding the market opportunity in breast cancer. Driving our strategy is the goal of further demonstrating that bavituximab can provide therapeutic benefit to available cancer treatments, regardless of whether those are traditional therapies such as chemotherapy and radiation, or the emerging novel class of immuno-oncology agents. In today’s update, it is evident that we are moving aggressively to compile a significant body of clinical evidence to support bavituximab’s utility in multiple cancers and across a range of treatment regimens. By doing so, we hope to optimally position bavituximab for success.”
The current status updates are as follows. For bavituximab in NSCLC, Peregrine’s Phase III SUNRISE (Stimulating ImmUne RespoNse thRough BavItuximab in a PhaSE III Lung Cancer Study) trial is evaluating the use of bavituximab and docetaxel in patients with previously treated locally advanced or metastatic non-squamous NSCLC. Peregrine expects that the first interim analysis (33% of targeted number of deaths) will be conducted in early 2016 and the second interim analysis (50% of targeted number of deaths) in mid-2016. The final analysis, which will trigger the unblinding of the study data, is currently projected to occur at the end of 2016.
Go home Loof.... That Wal-Mart is closing for good soon... Along with 280 others.. Get your licker, go sit on your porch, sit back and wait for the boom.
Been there done that... Won't happen.
I am a cancer victim... I can't stand the thought of investors shorting bio stocks... Especially ones with a promising cancer drug.
Some are hoping it takes as long as 2018 or longer... They love to short.
Yeah, 2017 give or take a few months... Sooner or later My friend... All I can do now is keep loading up.
For reasons like this.... Now I can buy pphm at a much lower price than I could if I took that money and invested it over the course of the year... It just happens to work out good this time around.
Guess we'll have to wait and see then... I'm taking 60% of my tax return and investing it too.... Sooner or later we'll start heading north.
Everyone just keeps buying more because it is doing so well.
I think your wrong about this quote.... People keep buying because the pps is so cheap and most believe pphm will eventually do well.... Very well.
My whole 401k portfolio has been basically in cash since March 2015... The only money I see going down is PPHM.
PS targeting agent (2aG4)? That's another code name for Bavi?
Who thinks the Sunrise trial is gonna fail?....
Maybe they plan to use the $5,000-$8,000 to publish that PR on something else... Guess it would be a waste of money if you can just go on Clinical.gov and see.
Nice to see Sunrise fully enrolled... Great job Steve!! You were definitely on target and hit the outside edge of the bullseye!! Well done.
The IBB hit a 52 week low today...eom
Watch the rebound starting Wednesday or Thursday... Thank you.
Anyone notice the IBB is close to it's 52 week low just like us?? And I always thought it was just Peregrine.
Boy sometimes I just feel like giving up on this company.. eom
Steve Kings presentation was awesome... That right there was the best I've heard coming from him... Ever.
Anyone remember seeing this?
Invest Ophthalmol Vis Sci. 2015 Nov 1;56(12):7137-45. doi: 10.1167/iovs.15-17302.
Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo.
Li T1, Aredo B2, Zhang K3, Zhong X2, Pulido JS4, Wang S5, He YG2, Huang X6, Brekken RA7, Ufret-Vincenty RL2.
Author information
Abstract
PURPOSE:
Choroidal neovascularization (CNV) accounts for 90% of cases of severe vision loss in patients with advanced age-related macular degeneration. Identifying new therapeutic targets for CNV may lead to novel combination therapies to improve outcomes and reduce treatment burden. Our goal was to test whether phosphatidylserine (PS) becomes exposed in the outer membrane of choroidal neovascular endothelium, and whether this could provide a new therapeutic target for CNV.
METHODS:
Choroidal neovascularization was induced in C57BL/6J mice using laser photocoagulation. Choroidal neovascularization lesions costained for exposed PS and for intercellular adhesion molecule 2 (or isolectin B4) were imaged in flat mounts and in cross sections. The laser CNV model and a choroidal sprouting assay were used to test the effect of PS-targeting antibodies on choroidal angiogenesis. Choroidal neovascularization lesion size was determined by intercellular adhesion molecule 2 (ICAM-2) staining of flat mounts.
RESULTS:
We found that PS was exposed in CNV lesions and colocalized with vascular endothelial staining. Treatment with PS-targeting antibodies led to a 40% to 80% reduction in CNV lesion area when compared to treatment with a control antibody. The effect was the same as that seen using an equal dose of an anti-VEGF antibody. Results were confirmed using the choroid sprouting assay, an ex vivo model of choroidal angiogenesis.
CONCLUSIONS:
We demonstrated that PS is exposed in choroidal neovascular endothelium. Furthermore, targeting this exposed PS with antibodies may be of therapeutic value in CNV.
D Strong.... Why isn't there anything out there that has promise for this little boy?... If someone is gonna die... Anything in clinical trials should be used to try and help a life... I just don't get it.
I am so glad I moved all 28 years of my 401k savings into a money market fund last March... Just hoping to jump back in at the bottom.... I haven't lost a dime... But as for pphm... I'm down about 20% from my average.
I heard Cramer say that once... eom
You're wasting your time counting days... You know as well as we do... They will not get delisted..Next.
New Drug Application (NDA)/ Biologics License Application (BLA)
If the drug proves to be safe and effective, the company then files an NDA or BLA with the FDA. NDAs and BLAs are typically 100,000 pages long and include results of human and animal trials as well as information on how the drug is manufactured. It usually takes the FDA 1-2 years to complete the review process and approve a drug.
I think he may have said 50,000 pages.
Is it against ihub policy to wager a bet??... It is on the subject of pphm... I'm willing to place a $100.00 bet with Lemmy that pphm will not get delisted... No way, no how!...
I'm 90% positive he said 500,000 pages too.... And it was webcasted.. He went into long details on how it was done.
“I know how the system works -- I know what mistakes you shouldn’t make, and I make sure you don’t make those mistakes,” Garnick says. “My view is the FDA is my friend. I am not an adversary.”
Garnick will be a huge part of the BLA submission... Maybe not write it, but it will most likely be written from his words.
Well my order won't get fill at them there levels!!.... Lol... I'm placed @ $1.02.